Gainers

• CytoMed Therapeutics (NASDAQ:GDTC) stock increased by 21.6% to $1.01 during Wednesday's after-market session. The market value of their outstanding shares is at $9.9 million.
• ALPS Group (NASDAQ:ALPS) shares moved upwards by 7.78% to $0.99. The company's market cap stands at $160.4 million.
• Azitra (AMEX:AZTR) stock increased by 6.84% to $0.24. The market value of their outstanding shares is at $2.5 million.
• AlphaTON Capital (NASDAQ:ATON) stock rose 4.88% to $0.53. The market value of their outstanding shares is at $7.9 million.
• aTyr Pharma (NASDAQ:ATYR) stock moved upwards by 4.02% to $0.92. The market value of their outstanding shares is at $94.0 million.
• Liminatus Pharma (NASDAQ:LIMN) stock rose 3.49% to $1.48. The market value of their outstanding shares is at $28.9 million.

Losers

• Evogene (NASDAQ:EVGN) stock fell 7.3% to $1.01 during Wednesday's after-market session. The company's market cap stands at $9.0 million.
• MAIA Biotechnology (AMEX:MAIA) shares decreased by 5.56% to $2.02. The market value of their outstanding shares is at $74.0 million.
• Halozyme Therapeutics (NASDAQ:HALO) stock declined by 5.5% to $73.65. The market value of their outstanding shares is at $8.9 billion.
• Smith & Nephew (NYSE:SNN) stock fell 5.19% to $33.27. The market value of their outstanding shares is at $14.5 billion.
• Profusa (NASDAQ:PFSA) stock fell 4.42% to $0.08. The market value of their outstanding shares is at $7.9 million.
• Vivos Therapeutics (NASDAQ:VVOS) shares fell 4.01% to $1.44. The company's market cap stands at $17.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.